A real-world study of the efficacy and safety of linezolid versus vancomycin in the treatment of Enterococcal bloodstream infections
10.12173/j.issn.1005-0698.202403062
- VernacularTitle:利奈唑胺与万古霉素治疗肠球菌血流感染疗效和安全性的真实世界研究
- Author:
Bingying TANG
1
;
Maoli YI
;
Ting GAO
;
Xuechen HUO
Author Information
1. 烟台毓璜顶医院药学部(山东烟台 264000)
- Keywords:
Bloodstream infection;
Enterococci;
Linezolid;
Vancomycin;
Efficacy;
Safety;
Propensity score matched
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(7):770-777
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of linezolid and vancomycin in the treatment of hospitalized patients with Enterococcus bloodstream infection,to provide medication choices for clinical practice.Methods The clinical data of 99 inpatients with Enterococcus bloodstream infection in Yantai Yuhuangding Hospital from June 2019 to June 2023 were retrospectively collected,and the patients were divided into linezolid group and vancomycin group according to the drug used.confounding factors were controlled by propensity score matching method.The clinical efficacy,inflammatory factor levels,and adverse reactions of the two groups were compared.Results After using propensity score matching,25 patients were assigned to both linezolid group and vancomycin group.There was no significant difference in the effective rate,30-day mortality,incidence of adverse reactions and inflammatory factor levels between the two groups(P＞0.05).Conclusion In the treatment of patients with Enterococcus bloodstream infection,the efficacy and safety of linezolid and vancomycin are the same.Linezolid can be a prioritized medicine when vancomycin causes nephrotoxicity and concentration does not meet the standard or exceeds the standard.Due to limitation of sample size and information collection,more high-quality studies are required to verify above conclusions.
